Therapeutic Target Details
| Target ID: | T29 |
| Target Name: | Fibroblast growth factor 19 |
| Synonyms: | FGF-19; FGF19 |
| GENE: | FGF19 |
| Action: | variant |
| Class: | Secreted |
| UniProtKB ID: | O95750 |
| Entry Name: | FGF19_HUMAN |
| Related Drugs: | NGM282 |
| Mechanism: | Human FGF19 is a gastrointestinal hormone that regulates bile acid synthesis, glucose metabolism and hepatic fatty acid oxidation, and is known to be a target of FXR; Fibroblast growth factor 19 (FGF-19) plays a central role in regulating bile acids and energy metabolism in the liver via FGF receptor 4. |
| Reference (PMIDs): | 32781086; 26567701 |
| Compound ID | Source ID | Source Type | Compound Name | Molecular Weight | Molecular Formula | Molecular Species |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00151 | 35208205 | Metabolites | A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver. | Details |
| A01487 | 34727818 | Expert Opin Ther Targets | A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). | Details |
| A01793 | 34615727 | Gut | Novel therapeutic targets for cholestatic and fatty liver disease. | Details |
| A03364 | 34027340 | JHEP Rep | Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. | Details |
| A03701 | 33898959 | JHEP Rep | Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. | Details |
| A04406 | 33630750 | Eur J Endocrinol | MECHANISMS IN ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases. | Details |
| A04783 | 33506572 | Liver Int | Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease. | Details |
| A06122 | 32998095 | Diabetes Metab Syndr | Pathophysiological mechanisms underlying MAFLD. | Details |
| A06684 | 32781086 | Gastroenterology | Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. | Details |
| A08004 | 32282030 | Br Med Bull | Obeticholic acid-a new therapy in PBC and NASH. | Details |
| A08065 | 32258945 | Hepatol Commun | Bile Acid Diarrhea and NAFLD: Shared Pathways for Distinct Phenotypes. | Details |
| A08115 | 32241197 | Expert Rev Gastroenterol Hepatol | Obeticholic acid for the treatment of nonalcoholic steatohepatitis. | Details |
| A08745 | 32003601 | Am J Physiol Gastrointest Liver Physiol | Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dysbiosis and hyperplasia in a novel pig model of pediatric NASH. | Details |
| A09661 | 31655133 | J Hepatol | β-Klotho gene variation is associated with liver damage in children with NAFLD. | Details |
| A10806 | 31181641 | J Clin Med | Bile Acid and Fibroblast Growth Factor 19 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Sleeve Gastrectomy. | Details |
| A11551 | 30847736 | Curr Obes Rep | Changes in Bile Acid Metabolism, Transport, and Signaling as Central Drivers for Metabolic Improvements After Bariatric Surgery. | Details |
| A11649 | 30805949 | Hepatology | NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis. | Details |
| A11919 | 30682184 | PLoS One | Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. | Details |
| A12767 | 30297626 | Int J Mol Sci | Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. | Details |
| A12898 | 30235807 | Diseases | Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD. | Details |